SU-ASME
Artificial intelligence Supporting CAncer Patients across Europe
ASME (Artificial intelligence Supporting CAncer Patients across Europe), is a sub-project of the Horizon 2020 project ASCAPE (Artificial intelligence Supporting CAncer Patients across Europe), funded by the European Commission.
ASME will focus on markers that can predict the possibility of developing side effects as well as progression of the melanoma during adjuvant therapy. Work will be based on a Karolinska University Hospital (KIH) retrospective dataset including data from a cohort of melanoma patients that received adjuvant therapy in the period between 2019 and 2021.
Zelus role and contribution:
Zelus oversaw the execution of the project, ensured the timely delivery of actions and deliverables and handled communications with the ASCAPE Consortium. It also prepared the technical architecture of ASME/ASCAPE, highlighting both the as-is situation with the existing parts of ASCAPE, as well as the to-be situation, where it introduced new components and APIs.
- Key Concepts: AI for cancer patients, ML-based personalized predictions and interventions, FHIR7 standards
- Website: ASME
- Duration: 9 Months
- Start Date: 01/03/2022
